Free Digital Markets
Archive

October 24, 2025

Browsing
Investing

Sun Summit Minerals to Present at the 51st Annual New Orleans Investment Conference, November 2-5, 2025

By

Sun Summit Minerals Corp. (TSXV: SMN,OTC:SMREF) (OTCQB: SMREF) (‘Sun Summit’ or the ‘Company’) is pleased to announce that it will be attending and presenting at the 51st Annual New Orleans Investment Conference, taking place November 2–5, 2025 at the Hilton New Orleans Riverside.

Niel Marotta, CEO and Director, will host a Sunrise Session presentation on Tuesday, November 4 at 7:15 AM (Churchill B2), where he will share updates on the Company’s flagship JD Project in British Columbia’s Toodoggone District, following the completion of a successful 2025 exploration season.

Space is limited. Investors are invited to RSVP by October 31 to info@sunsummitminerals.com, and to visit Sun Summit at Booth #229 throughout the conference.

The New Orleans Investment Conference brings together leading analysts, newsletter writers, and investors to discuss emerging opportunities across all major asset classes. Register today at https://neworleansconference.com/online-registration/.

About the JD Project

The JD Project is located in the Toodoggone mining district in north-central British Columbia, a highly prospective deposit-rich mineral trend. The project covers an area of over 15,000 hectares and is in close proximity to active exploration and development projects, such as Thesis Gold’s Lawyers and Ranch projects, TDG Gold’s Baker-Shasta projects, Amarc Resource’s AuRORA project, Centerra’s Gold’s Kemess East and Underground projects, as well as the past-producing Kemess open pit copper-gold mine.

The project is 450 kilometres northwest of the city of Prince George, and 25 kilometres north of the Sturdee airstrip. It is proximal to existing infrastructure in place to support the past-producing Kemess mine, including roads and a hydroelectric power line.

The JD Project is in a favourable geological environment characterized by both high-grade epithermal gold and silver mineralization, as well as porphyry-related copper and gold mineralization. Some historical exploration, including drilling, geochemistry and geophysics, has been carried out on the property, however the project area is largely underexplored.

About Sun Summit

Sun Summit Minerals (TSXV: SMN,OTC:SMREF) (OTCQB: SMREF) is a mineral exploration company focused on the discovery, expansion and advancement of district-scale gold and copper assets in British Columbia. The Company’s diverse portfolio includes its flagship JD Project and the nearby Theory Project in the Toodoggone region of north-central B.C., as well as the Buck Project in central B.C.

Further details are available at www.sunsummitminerals.com.

On behalf of the board of directors

Niel Marotta
Chief Executive Officer & Director
info@sunsummitminerals.com

For further information, contact:

Matthew Benedetto, Simone Capital
mbenedetto@simonecapital.ca
Tel. 416-817-1226

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

Statements contained in this news release that are not historical in nature may be ‘forward-looking information’ within the meaning of applicable Canadian securities legislation (‘forward-looking statements ‘), which involve risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements, by their nature, require Sun Summit to make certain assumptions and necessarily involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in these forward-looking statements. Forward-looking statements are not guarantees of performance. Words such as ‘may’, ‘will’, ‘would’, ‘could’, ‘expect’, ‘believe’, ‘plan’, ‘anticipate’, ‘intend’, ‘estimate’, ‘continue’, ‘objective’, ‘strategy’, or the negative or comparable terminology, as well as terms usually used in the future and the conditional, are intended to identify forward-looking statements. Information contained in forward-looking statements is based upon certain material assumptions that were applied in drawing a conclusion or making a forecast or projection, including the assumptions, qualifications, limitations or statements relating to the pending results of the drill holes, the success of the exploration program, the impressive results of the drill campaign, the ability of exploration activities (including drilling) to accurately predict mineralization, future drill programs and high-priority targets, our timing and ability to receive assay results, the reliability of historical information that cannot be independently verified by Sun Summit, interests in the JD Project, errors in geological modelling, and the adjacent properties having any significance to the projects in which Sun Summit has an interest. There is significant risk that the forward-looking statements will not prove to be accurate, that the management’s assumptions may not be correct and that actual results may differ materially from such forward-looking statements. These forward-looking statements are based on a number of assumptions which may prove to be incorrect which, without limiting the generality of the following, include: the Company’s ability to obtain assay results for the completed drill program; the anticipated results varying from current indications, including the already released drill results; risks inherent in exploration activities; volatility and sensitivity to market prices; volatility and sensitivity to capital market fluctuations; and fluctuations in metal prices. Accordingly, readers should not place undue reliance on the forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof or the dates specifically referenced in this news release, where applicable. Except as required by applicable securities laws and regulation, Sun Summit disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. All forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/271649

News Provided by Newsfile via QuoteMedia

This post appeared first on investingnews.com

Keep Reading
By
Investing

Quimbaya Gold Announces C$10 Million Bought Deal Financing

By

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES./

Quimbaya Gold Inc. (‘Quimbaya’ or the ‘Company’) (CSE: QIM,OTC:QIMGF) (OTCQB: QIMGF) (FSE: K05) is pleased to announce that it has entered into an agreement with Stifel Canada to act as sole underwriter and bookrunner (the ‘Underwriter’), in connection with a ‘bought deal’ private placement of 14,300,000 units of the Company  (the ‘LIFE Units’) at a price of C$0.70 per LIFE Unit (the ‘Offering Price’) for aggregate gross proceeds of C$10,010,000 (the ‘Offering’), with the LIFE Units to be issued pursuant to the Listed Issuer Financing Exemption (as defined below). 

The Company has granted to the Underwriter an option, exercisable up to 48 hours prior to the closing date, to purchase for resale up to an additional 15% of LIFE Units at the Offering Price for additional gross proceeds of up to C$1,501,500. 

Each LIFE Unit will consist of one common share (a ‘Common Share‘) and one-half (½) of one Common Share purchase warrant (each whole warrant, a ‘Warrant‘) of the Company. Each Warrant will be exercisable to acquire one Common Share for a period of 36 months following the closing date of the Offering at an exercise price of C$1.00 per common share.

The net proceeds from the Offering are expected to be used to advance the Company’s exploration programs, including drilling at the Tahami South project and follow-up work on regional copper-gold and gold targets, as well as for general working capital.

Subject to compliance with applicable regulatory requirements and in accordance with National Instrument 45-106 – Prospectus Exemptions (‘NI 45-106‘), the LIFE Units will be offered for sale to purchasers resident in Canada other than Quebec and/or other qualifying jurisdictions pursuant to the listed issuer financing exemption under Part 5A of NI 45-106 (the ‘Listed Issuer Financing Exemption‘). Because the Offering is being completed pursuant to the Listed Issuer Financing Exemption, the LIFE Units issued pursuant to the Offering will not be subject to a hold period pursuant to applicable Canadian securities laws. There is an offering document related to the Offering that can be accessed under the Company’s issuer profile on SEDAR+ at www.sedarplus.ca and on the Company’s website at quimbayagold.com. Prospective investors should read the offering document before making an investment decision.

The Offering is scheduled to close on or about November 4, 2025 (the ‘Closing Date‘) and is subject to certain conditions including, but not limited to, the receipt of all necessary regulatory and other approvals including the acceptance of the Canadian Securities Exchange.

The securities referred to in this news release have not been and will not be registered under the United States Securities Act of 1933, as amended (the ‘U.S. Securities Act‘), or any state securities laws and may not be offered or sold within the United States or to, or for the account or benefit of, ‘U.S. Persons’ (as such term is defined in Regulation S under the U.S. Securities Act) absent such registration or an applicable exemption from the registration requirements of the U.S. Securities Act. This news release does not constitute an offer for sale of securities for sale, nor a solicitation for offers to buy any securities. Any public offering of securities in the United States must be made by means of a prospectus containing detailed information about the company and management, as well as financial statements.

About Quimbaya 

Quimbaya aims to discover gold resources through exploration and acquisition of mining properties in the prolific gold mining districts of Colombia. Managed by an experienced team in the mining sector, Quimbaya is focused on three projects in the regions of Segovia (Tahami Project), Puerto Berrio (Berrio Project), and Abejorral (Maitamac Project), all located in Antioquia Province, Colombia.

Quimbaya Gold Inc.

Follow on X @quimbayagoldinc
Follow on LinkedIn @quimbayagold
Follow on YouTube @quimbayagoldinc
Follow on Instagram @quimbayagoldinc
Follow on Facebook @quimbayagoldinc

Cautionary Statements

Certain statements contained in this press release constitute ‘forward-looking information’ as that term is defined in applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. Generally, but not always, forward-looking statements and information can be identified by the use of forward-looking terminology such as ‘intends’, ‘expects’ or ‘anticipates’, or variations of such words and phrases or statements that certain actions, events or results ‘may’, ‘could’, ‘should’, ‘would’ or ‘occur’. Forward-looking statements herein include statements and information regarding the closing of the Offering, Offering’s intended use of proceeds, any exercise of Warrants, the future plans for the Company, including any expectations of growth or market momentum, future expectations for the gold sector generally, the Colombian gold sector more particularly, or how global or local market trends may affect the Company, intended exploration on any of the Company’s properties and any results thereof, the strength of the Company’s mineral property portfolio, the potential discovery and potential size of the discovery of minerals on any property of the Company’s, including Tahami South, the aims and goals of the Company, and other forward-looking information. Forward-looking information by its nature is based on assumptions and involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Quimbaya to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements or information. These assumptions include, but are not limited to, that the Company’s exploration and other activities will proceed as expected. The future outcomes that relate to forward-looking statements may be influenced by many factors, including but not limited to: future planned development and other activities on the Company’s mineral properties; an inability to finance the Company; obtaining required permitting on the Company’s mineral properties in a timely manner; any adverse changes to the planned operations of the Company’s mineral properties; failure by the Company for any reason to undertake expected exploration programs; achieving and maintaining favourable relationships with local communities; mineral exploration results that are poorer or better than expected; prices for gold remaining as expected; currency exchange rates remaining as expected; availability of funds for the Company’s projects; prices for energy inputs, labour, materials, supplies and services (including transportation); no labour-related disruptions; no unplanned delays or interruptions in scheduled construction and production; all necessary permits, licenses and regulatory approvals are received in a timely manner; the Offering proceeds being received as anticipated; all requisite regulatory and stock exchange approvals for the Offering are obtained in a timely fashion; investor participation in the Offering; and the Company’s ability to comply with environmental, health and safety laws. Although Quimbaya’s management believes that the assumptions made and the expectations represented by such information are reasonable, there can be no assurance that the forward-looking information will prove to be accurate. Furthermore, should one or more of the risks, uncertainties or other factors materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in forward-looking statements or information. Readers are cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Quimbaya as of the date of this news release and, accordingly, is subject to change after such date. Except as required by law, Quimbaya does not expect to update forward-looking statements and information continually as conditions change.

SOURCE Quimbaya Gold Inc.

View original content: http://www.newswire.ca/en/releases/archive/October2025/23/c7762.html

News Provided by Canada Newswire via QuoteMedia

This post appeared first on investingnews.com

Keep Reading
By
Investing

Top 4 Canadian Biotech Stocks of 2025

By

Biotech is a dynamic industry that is driving scientific advances and innovation in healthcare. In Canada, the biotech sector is home to companies pursuing cutting-edge therapies and medical technologies.

Read on to learn what’s been driving these Canadian biotech firms.

1. Eupraxia Pharmaceuticals (TSX:EPRX)

Year-on-year gain: 141.23 percent
Market cap: C$410.85 million
Share price: C$8.25

Eupraxia Pharmaceuticals is developing clinical candidates that employ its DiffuSphere technology, which delivers treatments to the targeted tissues.

The company’s candidates are currently EP-104GI for eosinophilic esophagitis and EP-104IAR for knee osteoarthritis, and it is exploring the use of its technology for other active compounds as well.

Eupraxia added EP-104GI to its pipeline through its acquisition of EpiPharma Therapeutics in late 2023. The company has continued to advance the treatment through clinical trials in 2025 and released multiple rounds of positive data from its Phase 1b/2a trial cohorts.

In July, Eupraxia dosed its first patient after advancing its investigation to Phase 2b trials based on safety and efficacy data from the earlier Phase 2a patient cohorts. Top-line results from the Phase 2b study are anticipated in the second half of 2026.

In September, the company shared data from the highest-dose cohort of the still ongoing Phase 1b/2a trials, reporting that the group saw the largest improvements so far.

2. Bright Minds Biosciences (CSE:DRUG)

Year-on-year gain: 103.17 percent
Market cap: C$683.67 million
Share price: C$92.95

Bright Minds Biosciences is developing novel serotonin agonists targeting neurocircuit abnormalities linked to neuropsychiatric disorders and epilepsy, designing next-generation treatments that aim to retain the therapeutic benefits of psychedelics while minimizing side effects.

Its lead candidate, BMB-101, a selective 5-HT2C receptor agonist, has shown encouraging preclinical efficacy by stopping seizures in an epilepsy mouse model, evaluated jointly with Firefly Neuroscience (NASDAQ:AIFF).

The company’s stock surged nearly 1,500 percent in October 2024 following H. Lundbeck’s acquisition announcement of a competitor focused on similar targets. Strengthening its epilepsy expertise, Bright Minds expanded its scientific advisory board in early 2025 by adding five leaders in the field.

Ongoing clinical progress and strategic growth initiatives position Bright Minds as a promising contender in the neuropsychiatric treatment landscape.

3. Hemostemix (TSXV:HEM)

Year-on-year gain: 31.25 percent
Market cap: C$18.40 million
Share price: C$0.11

Hemostemix is a clinical-stage biotech company focused on developing autologous stem cell therapies, meaning the treatments use a patient’s own cells to theoretically enhance safety and efficacy.

Its main product, ACP-01, is an autologous cell therapy designed to promote tissue repair and regeneration in areas affected by diseases, including a range of heart diseases.

The company announced its first advanced sales orders for ACP-01 in Q1 2025 and has been working to expand internationally and attract new investment.

Hemostemix secured the regulatory green light for commercial sales in Florida after the state passed Senate Bill 1768. The bill creates a framework in which healthcare providers can administer stem cell therapies that had not yet been approved by the US Food and Drug Administration (FDA) but meet the bill’s guidelines.

The company now offers commercial ACP-01 treatments for ischemic pain in the state under the name VesCell, with sales forecasted to reach C$22.5 million in 2026. Operational plans target cash flow positivity by Q4 2026, supported by a growing physician network and commercial pipeline.

Additionally, Hemostemix is currently collaborating with Firefly Neuroscience on a Phase 1 clinical trial of ACP-01 for vascular dementia.

4. NervGen (TSXV:NGEN)

Year-on-year gain: 79.92 percent
Market cap: C$300.97 million
Share price: C$4.39

NervGen is a clinical-stage Canadian biotechnology company that focuses on developing innovative treatments to enable the nervous system to repair itself following damage from injury or disease.

The company’s core technology targets a mechanism that hinders nervous system repair. When the nervous system is damaged, chondroitin sulfate proteoglycans (CSPG) form a “scar.” Initially, CSPGs help contain damage, but their long-term interaction with the PTPσ receptor inhibits repair.

NervGen’s lead drug candidate, NVG-291, is designed to relieve these inhibitory effects to promote nervous system repair. It received fast-track designation from the US FDA.

NervGen is advancing NVG-291 in a Phase 1b/2a clinical trial for spinal cord injury (SCI) and reported positive data from the chronic cohort in June.

NVG-300, a newer preclinical candidate, is being evaluated for ischemic stroke and SCI.

Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Keep Reading
By